Evotec SE

NasdaqGS:EVO Stock Report

Market Cap: US$1.6b

Evotec Future Growth

Future criteria checks 4/6

Evotec is forecast to grow earnings and revenue by 74.3% and 12.1% per annum respectively. EPS is expected to grow by 76.1% per annum. Return on equity is forecast to be 4.3% in 3 years.

Key information

74.3%

Earnings growth rate

76.1%

EPS growth rate

Life Sciences earnings growth18.4%
Revenue growth rate12.1%
Future return on equity4.3%
Analyst coverage

Good

Last updated15 Nov 2024

Recent future growth updates

Recent updates

Evotec: Weak Performance, But Long-Term Potential Is There

Aug 30

Evotec: Still A Speculative Buy After A Significant Decline

Apr 24

Amgen joins TIAP, Evotec at innovation hub for forming life science companies

Oct 17

Evotec stock dips despite US DoD contract up to $49.9M to develop antibody for plague

Sep 20

Evotec to acquire Central Glass Germany to bolster drug substance manufacturing

Aug 25

Evotec stock falls amid pact with Alpine for commercial process for potential lupus drug ALPN-303

Aug 10

Boehringer, Evotec, bioMérieux form joint venture Aurobac to combat antimicrobial resistance

Jul 06

Earnings and Revenue Growth Forecasts

NasdaqGS:EVO - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,02610581399
12/31/2025905-38-1729
12/31/2024806-145-254-539
9/30/2024777-171-209-36N/A
6/30/2024788-171-246-55N/A
3/31/2024777-91-224-12N/A
12/31/2023781-84-18036N/A
9/30/2023821-95-188-14N/A
6/30/2023798-103-246-42N/A
3/31/2023800-116-39143N/A
12/31/2022751-17624206N/A
9/30/2022698-180121297N/A
6/30/20226842194322N/A
3/31/20226509058183N/A
12/31/20216182163122N/A
9/30/2021571247-5886N/A
6/30/2021541112-5093N/A
3/31/202151542-9920N/A
12/31/20205016-5445N/A
9/30/202048514-462N/A
6/30/202047035046N/A
3/31/2020462424382N/A
12/31/2019446381042N/A
9/30/201941961129N/A
6/30/2019404774674N/A
3/31/201939894109139N/A
12/31/201837584128156N/A
9/30/201837063109135N/A
6/30/201833831N/A80N/A
3/31/201829420N/A19N/A
12/31/201726423N/A11N/A
9/30/201721528N/A64N/A
6/30/201719335N/A73N/A
3/31/201717836N/A74N/A
12/31/201616528N/A67N/A
9/30/201616018N/A5N/A
6/30/20161486N/A-6N/A
3/31/201614417N/A-2N/A
12/31/201512817N/A16N/A
9/30/201511912N/A19N/A
6/30/201510411N/A23N/A
3/31/201593-4N/A9N/A
12/31/201489-7N/A-4N/A
9/30/201485-29N/A6N/A
6/30/201489-25N/A2N/A
3/31/201486-27N/A1N/A
12/31/201386-25N/A7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EVO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: EVO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: EVO is expected to become profitable in the next 3 years.

Revenue vs Market: EVO's revenue (12.1% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: EVO's revenue (12.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: EVO's Return on Equity is forecast to be low in 3 years time (4.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y